Daily Newsletter

19 April 2024

Daily Newsletter

19 April 2024

Lumicell secures FDA approval for imaging platform

The LumiSystem is designed to improve accuracy in detecting residual cancer during lumpectomy surgeries.

Archana Rani April 19 2024

Lumicell has received approval for its new drug application (NDA) for LUMISIGHT optical imaging agent and premarket approval (PMA) application for Lumicell direct visualisation system (DVS) from the US Food and Drug Administration (FDA).

The LUMISIGHT optical imaging agent and Lumicell DVS are together referred to as LumiSystem, which aims to assist surgeons in detecting residual cancer cells during breast cancer surgeries.

Lumicell said the LumiSystem demonstrated an 84% diagnostic accuracy in identifying cancerous tissue that might have been missed during lumpectomy surgery and sparing some patients from second surgeries.

The LumiSystem is indicated for fluorescence imaging in adult breast cancer patients as an adjunct tool for intraoperative detection of cancerous tissue within the resection cavity after the removal of the main specimen during the surgery.

The system’s safety was established using data from more than 700 breast cancer patients across five clinical studies at leading academic and regional community cancer centres in the US. 

The most commonly found side effects with the use of LUMISIGHT included hypersensitivity and urine discolouration, with serious hypersensitivity reactions, including anaphylaxis, also being a possibility.

Results from the Investigation of Novel Surgical Imaging for Tumor Excision (INSITE) pivotal trial, published in NEJM Evidence, supported the efficacy of the system.

Lumicell president and CEO Howard Hechler said: “We are immensely proud of the dual approval of LUMISIGHT and Lumicell DVS – we believe this is the first drug-device combination product approved in over a decade to have followed both of the FDA's most stringent NDA and PMA review processes.

“With the FDA’s approval, LumiSystem is now the first and only imaging combination product capable of detecting cancerous tissue where it matters most, inside the breast cavity.”

Earlier, LUMISIGHT and Lumicell DVS secured FDA Fast Track and Breakthrough Device designations, respectively.

Last May, the FDA accepted the PMA application for Lumicell’s breast cancer detection assistance device.






Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors


Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.